Latest UpdatesProgenicyte, University of Central Florida, School of Medicine spinoff venture company 実写 版 ブラック ジャック a developer of stem cell regenerative medicine establishes a Japanese corporation in KOBE Biomedical Innovation Cluster

Progenicytewas established to commercialize therapeutic compounds 実写 版 ブラック ジャック cutting edge medical technologies (over 60 patents 実写 版 ブラック ジャック patent-pending with 28 granted international patents) developed by Dr. Kiminobu Sugaya, Professor 実写 版 ブラック ジャック Head of the Neuroscience at Burnett School of Biomedical Science, College of Medicine, University of Central Florida. Currently, the company is focusing the commercialization of 'KS-217' , a regenerative drug for treating neurodegenerative diseases, including Alzheimer’s 実写 版 ブラック ジャック Parkinson’s diseases by increasing endogenous-neutral stem cells in the brain.

'KS-217' may become a new therapeutic measure for neurological disorders, which are considered difficult to treat. The drug based regeneration therapy st実写 版 ブラック ジャックs out as it can be orally administered 実写 版 ブラック ジャック does not require cell culture or surgery, which are always associated with other cell therapies. It is confirmed to be highly effective in animal models without any side effect. In addition, it has been demonstrated that 'KS-217' also increases endogenous mesenchymal stem cells. Thus, it can be locally applied to increase hair growth 実写 版 ブラック ジャック rejuvenation of skin, 実写 版 ブラック ジャック also regenerate cornea 実写 版 ブラック ジャック treat bone fractures without transplantation of the cells.

In January 2020, Progenicyte establishedProgenicyte Japan Co., Ltdas the first of its overseas base in the KOBE Biomedical Innovation Cluster in Hyogo Prefecture. The company is aiming to widely distribute benefits of their technologies to the society by seeking Japanese partners, who wish to invest in the company or conduct joint ventures with the company for their commercialization.
Progenicyte Japan Co., Ltd is thriving to contribute to improve the quality of life for the patients 実写 版 ブラック ジャック their families in ‘The era of 100 years life span’ by marketing ‘KS-217’ 実写 版 ブラック ジャック other new medical technologies developed in the university, 実写 版 ブラック ジャック licensing their patents.

The JETROオンライン ブラック ジャックn Business Support Center (IBSC)assisted the establishment of Progenicyte Japan Co., Ltd by providing a temporary office space, consultations on the registration, opportunities for business matching, information of the market, support on their public relation activities, 実写 版 ブラック ジャック introduction to the local governments.

New neurons produced from stem cells. (Blue nuclei counter staining; Green new neuronal marker, beta3-tubulin)